Atara Biotherapeutics (ATRA) Research & Development (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Research & Development came in at $164000.0 in Q1 2026, down 99.4% YoY from $27.4 million in Q1 2025, and up 173.54% on a QoQ basis from -$223000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Research & Development (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Research & Development data on file, last reported at $164000.0 in Q1 2026.
- Quarterly Research & Development fell 99.4% year-over-year to $164000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 million (down 92.37% YoY) and the FY2025 annual result came in at $37.4 million, down 75.28% from the prior year.
- Research & Development grew to $164000.0 in Q1 2026, from -$223000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $75.0 million in Q1 2022 to a low of -$223000.0 in Q4 2025.
- A 5-year average of $40.4 million and a median of $45.5 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development grew 17.02% — and 2025, when it tumbled 100.78%.
- Tracing ATRA's Research & Development over 5 years: stood at $62.5 million in 2022, then dropped by 20.66% to $49.6 million in 2023, then tumbled by 42.09% to $28.7 million in 2024, then plunged by 100.78% to -$223000.0 in 2025, then surged by 173.54% to $164000.0 in 2026.
- The last three Research & Development figures came in at $164000.0 (Q1 2026), -$223000.0 (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Atara Biotherapeutics | 140.71 Mn | 124.16 Mn | 439,000.00 | 1.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.35 Mn |
| Mar 31, 2026 | 164,000.00 |
| Dec 31, 2025 | -223,000.00 |
| Sep 30, 2025 | 2.93 Mn |
| Jun 30, 2025 | 7.31 Mn |
| Mar 31, 2025 | 27.43 Mn |
| Dec 31, 2024 | 28.72 Mn |
| Sep 30, 2024 | 43.92 Mn |
| Jun 30, 2024 | 33.33 Mn |
| Mar 31, 2024 | 45.51 Mn |
| Dec 31, 2023 | 49.60 Mn |
| Sep 30, 2023 | 56.89 Mn |
| Jun 30, 2023 | 56.14 Mn |
| Mar 31, 2023 | 62.16 Mn |
| Dec 31, 2022 | 62.52 Mn |
| Sep 30, 2022 | 70.16 Mn |
| Jun 30, 2022 | 64.90 Mn |
| Mar 31, 2022 | 74.96 Mn |
| Dec 31, 2021 | 79.13 Mn |
| Sep 30, 2021 | 70.33 Mn |